BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11766742)

  • 1. Treatment for complex atypical hyperplasia of the endometrium.
    Jobo T; Kawaguchi M; Imai M; Kuramoto H
    Eur J Gynaecol Oncol; 2001; 22(5):365-8. PubMed ID: 11766742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.
    Kaku T; Yoshikawa H; Tsuda H; Sakamoto A; Fukunaga M; Kuwabara Y; Hataeg M; Kodama S; Kuzuya K; Sato S; Nishimura T; Hiura M; Nakano H; Iwasaka T; Miyazaki K; Kamura T
    Cancer Lett; 2001 Jun; 167(1):39-48. PubMed ID: 11323097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.
    Emarh M
    Arch Gynecol Obstet; 2015 Dec; 292(6):1339-43. PubMed ID: 26015309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
    Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
    J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
    Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
    Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
    Tamauchi S; Kajiyama H; Utsumi F; Suzuki S; Niimi K; Sakata J; Mizuno M; Shibata K; Kikkawa F
    J Obstet Gynaecol Res; 2018 Jan; 44(1):151-156. PubMed ID: 29121428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
    Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
    Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations.
    Imai M; Jobo T; Sato R; Kawaguchi M; Kuramoto H
    Eur J Gynaecol Oncol; 2001; 22(3):217-20. PubMed ID: 11501776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
    Minaguchi T; Nakagawa S; Takazawa Y; Nei T; Horie K; Fujiwara T; Osuga Y; Yasugi T; Kugu K; Yano T; Yoshikawa H; Taketani Y
    Cancer Lett; 2007 Apr; 248(1):112-22. PubMed ID: 16919866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.
    Inoue O; Hamatani T; Susumu N; Yamagami W; Ogawa S; Takemoto T; Hirasawa A; Banno K; Kuji N; Tanaka M; Aoki D
    Reprod Biol Endocrinol; 2016 Jan; 14():2. PubMed ID: 26769300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women.
    Tabatabaie A; Karimi Zarchi M; Dehghani-Tafti M; Miratashi-Yazdi A; Teimoori S; Dehghani A
    Eur J Gynaecol Oncol; 2013; 34(6):552-5. PubMed ID: 24601050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
    Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
    Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias.
    Masuzawa H; Badokhon NH; Nakayama K; Konishi I; Nikaido T; Fujii S
    Cancer; 1994 Oct; 74(8):2321-8. PubMed ID: 7922983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
    Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
    BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.
    Gibbons WE; Thorneycroft IH
    J Reprod Med; 1999 Feb; 44(2 Suppl):203-8. PubMed ID: 11392033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy.
    Figueroa-Casas PR; Ettinger B; Delgado E; Javkin A; Vieder C
    Menopause; 2001; 8(6):420-3. PubMed ID: 11723414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organ preserving method in the management of atypical endometrial hyperplasia.
    Kobiashvili H; Charkviani L; Charkviani T
    Eur J Gynaecol Oncol; 2001; 22(4):297-9. PubMed ID: 11695813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.